Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 33 min ago
PreprintAll rights reservedbioRxiv

A COJEC-chemotherapy resistant model of Th-ALK(F1174L)/MYCN neuroblastoma offers insights into tumour immune evasion and development of the bone marrow metastatic niche

  • E. R. Tucker1
  • A. Lampis
  • J. Househam
  • D. Roberts
  • K. Barker
  • B. Martins da Costa
  • K. Greenslade
  • S. Mayfield
  • F. Lorenzi
  • E. Thorley
  • V. Tandon
  • N. S. Han
11 more authors
  • G. Emanuelli
  • M. Bourdim
  • G. Martin
  • N. Willumsen
  • M. Pannone
  • J. Pryce
  • P. Angelini
  • M. Yuneva
  • T. Graham
  • S. L. George
  • L. Chesler
  1. 1The Institute of Cancer Research, UK
Read full textPDFDOICite

Related

  1. Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
    Daniel J. George, Jasmina I. Ivanova, Maëlys Touya +6
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Microbiome-derived TOPOSCORE is associated with response to immune checkpoint inhibitor re-induction after chemotherapy in primary resistant metastatic melanoma
    Sebastian Haferkamp, Bastian Schilling, Lea Baumgart +12
    Cancer Immunology, Immunotherapy : CIIPeer-reviewedCC BY 4.0Full textOncologyPMC
  3. Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database.
    William Jacot, Pauline Macouillard, Suyuan Zhang +11
    Breast (Edinburgh, Scotland)Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Development and External Validation of a Machine Learning-Derived Risk Stratification Score for Metastatic Castration-Resistant Prostate Cancer
    Laura Castro-Labrador, Rafael Zamora, Sergio Szyldergemajn +5
    JCO Clinical Cancer InformaticsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  5. Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity
    Adrià Molero-Valenzuela, Isabel de Rojas-P, Guillem Pons +15
    npj Precision OncologyPeer-reviewedCC BYFull textNeurologyDOAJ

Cite

BibTeXRIS
BibTeX
@misc{tucker2026cojecchemotherapy,
  title = {{A COJEC-chemotherapy resistant model of Th-ALK(F1174L)/MYCN neuroblastoma offers insights into tumour immune evasion and development of the bone marrow metastatic niche}},
  author = {E. R. Tucker and A. Lampis and J. Househam and D. Roberts and K. Barker and B. Martins da Costa and K. Greenslade and S. Mayfield and F. Lorenzi and E. Thorley and V. Tandon and N. S. Han and G. Emanuelli and M. Bourdim and G. Martin and N. Willumsen and M. Pannone and J. Pryce and P. Angelini and M. Yuneva and T. Graham and S. L. George and L. Chesler},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.01.743331},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.01.743331v1},
}
RIS
TY  - UNPB
TI  - A COJEC-chemotherapy resistant model of Th-ALK(F1174L)/MYCN neuroblastoma offers insights into tumour immune evasion and development of the bone marrow metastatic niche
AU  - E. R. Tucker
AU  - A. Lampis
AU  - J. Househam
AU  - D. Roberts
AU  - K. Barker
AU  - B. Martins da Costa
AU  - K. Greenslade
AU  - S. Mayfield
AU  - F. Lorenzi
AU  - E. Thorley
AU  - V. Tandon
AU  - N. S. Han
AU  - G. Emanuelli
AU  - M. Bourdim
AU  - G. Martin
AU  - N. Willumsen
AU  - M. Pannone
AU  - J. Pryce
AU  - P. Angelini
AU  - M. Yuneva
AU  - T. Graham
AU  - S. L. George
AU  - L. Chesler
PY  - 2026
DA  - 2026/09/01
PB  - bioRxiv
DO  - 10.64898/2026.09.01.743331
UR  - https://www.biorxiv.org/content/10.64898/2026.09.01.743331v1
ER  -